Revance Therapeutics (RVNC) delivered earnings and revenue surprises of -5.71% and 11.60%, respectively, for the quarter ended Sept. Do the numbers hold clues to what lies ahead for the stock?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback